Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News NRX Pharmaceuticals Inc NRXP

Financial Services Healthcare
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of... see more

Recent & Breaking News (NDAQ:NRXP)

NRx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 14, 2023

PR Newswire August 7, 2023

NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101(TM) for Chronic Pain

PR Newswire August 7, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire June 27, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire June 23, 2023

NRx Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

PR Newswire June 20, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire June 15, 2023

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of NRx Pharmaceuticals, Inc. and Encourages Long-Term NRXP / BRPA Shareholders to Contact the Firm

PR Newswire June 15, 2023

NRx Pharmaceuticals Announces Closing of $6.28 Million Registered Direct Offering

PR Newswire June 9, 2023

NRx Pharmaceuticals Announces $6.28 Million Registered Direct Offering

PR Newswire June 6, 2023

NRx Pharmaceuticals to Host Corporate and Strategic Update Conference Call on Monday, June 5, 2023

PR Newswire June 2, 2023

NRXP SHAREHOLDER ALERT: Jakubowitz Law Notifies Shareholders of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire May 26, 2023

NRXP ALERT: Levi & Korsinsky, LLP Announces an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire May 25, 2023

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire May 24, 2023

NRXP ALERT: The Klein Law Firm Investigates the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire May 23, 2023

MERGER INVESTIGATION ALERT: The Law Offices of Vincent Wong Notify Investors of an Investigation into the Fairness of NRx Pharmaceuticals Inc.'s De-SPAC Merger

PR Newswire May 22, 2023

NRx Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update

PR Newswire May 16, 2023

NRx Pharmaceuticals Reschedules First Quarter 2023 Financial Results Conference Call

PR Newswire May 10, 2023

NRx Pharmaceuticals to Report First Quarter 2023 Financial Results on May 11, 2023

PR Newswire April 27, 2023

NRx Pharmaceuticals Reports Full Year 2022 Financial Results and Provides Business Update

PR Newswire March 30, 2023

NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression

PR Newswire March 27, 2023